Condition
    Effectiveness 1/5

    CoQ10 for Parkinson's Disease

    CoQ10 was the most promising supplement candidate in Parkinson's disease after early positive trials — and then the definitive trial happened. The QE3 study of 1200-2400 mg daily in 600 patients was stopped early for futility, showing no slowing of decline. Early promise did not survive proper testing.

    Overview

    CoQ10 was the most promising supplement candidate in Parkinson's disease after early positive trials — and then the definitive trial happened. The QE3 study of 1200-2400 mg daily in 600 patients was stopped early for futility, showing no slowing of decline. Early promise did not survive proper testing.

    Verdict

    Insufficient evidence

    The definitive 600-patient randomised trial was stopped for futility; high-dose CoQ10 does not slow Parkinson's.

    How It Works

    CoQ10 is a mitochondrial electron carrier and antioxidant, and mitochondrial dysfunction is central to dopamine neuron death — a coherent rationale that nonetheless failed to translate into clinical benefit.

    Dosing & Protocol

    Typical dose

    Recommended dose
    No dose recommended — 1200-2400 mg/day was tested and failed
    Expected timeframe
    Not applicable — no disease-modifying effect at any dose tested

    Protocol

    dose
    1200 mg/day and 2400 mg/day were tested in the definitive trials
    form
    Ubiquinone with vitamin E, taken in divided doses with food
    steps
    The evidence here is insufficient — in fact it is negative. An early small phase II study at 1200 mg/day hinted at slowed decline, and this drove years of use.,The NINDS QE3 phase III trial then randomised early Parkinson's patients to 1200 mg/day or 2400 mg/day of CoQ10 with vitamin E, and was stopped early for futility: there was no slowing of clinical decline versus placebo at either dose.,Do not spend money on high-dose CoQ10 for Parkinson's on the strength of the older pilot data.,Stay on dopaminergic therapy prescribed by your neurologist, and prioritise the intervention with real evidence for function in Parkinson's: structured, progressive exercise.,If you take CoQ10 for another reason, standard doses of 100-200 mg/day remain safe — just do not expect disease modification.
    timing
    Not applicable
    duration
    Not applicable

    Evidence

    What the studies say

    A 2002 pilot at 1200 mg suggested slowed decline, but the QE3 phase 3 trial found no benefit at 1200 or 2400 mg daily over 16 months and was halted for futility. The same pattern — positive pilot, negative definitive trial — played out for creatine (NET-PD) and vitamin E (DATATOP). Exercise remains the intervention with the strongest progression data.

    No studies are yet linked to both CoQ10 and Parkinson's Disease.

    Safety

    Caveats

    Never reduce or stop levodopa, dopamine agonists or MAO-B inhibitors to trial a supplement. CoQ10 interacts with warfarin (can lower INR) and lowers blood pressure additively — relevant because orthostatic hypotension is already common in Parkinson's. High doses are expensive and unproven. Insufficient pregnancy data.

    Less likely to help if

    All Parkinson's patients with respect to disease progression — the largest randomised trial found no benefit at up to 2400 mg/day.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.